Now Is A Good Time To Buy DICE Therapeutics Inc. (NASDAQ: DICE) – Marketing Sentinel
Home  »  Science   »  Now Is A Good Time To Buy DICE Therapeutics Inc. (...

Now Is A Good Time To Buy DICE Therapeutics Inc. (NASDAQ: DICE)

During the last session, DICE Therapeutics Inc. (NASDAQ:DICE)’s traded shares were 0.5 million. At the end of the trading day, the stock’s price was $17.48, reflecting an intraday gain of 6.98% or $1.14. The 52-week high for the DICE share is $40.50, that puts it down -131.69 from that peak though still a striking 23.4% gain since the share price plummeted to a 52-week low of $13.39. The company’s market capitalization is $701.47M, and the average trade volume was 346.34K shares over the past three months.

DICE Therapeutics Inc. (NASDAQ:DICE) trade information

DICE Therapeutics Inc. (DICE) registered a 6.98% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 6.98% in intraday trading to $17.48 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -0.46%, and it has moved by -6.02% in 30 days.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

DICE Therapeutics Inc. (DICE) estimates and forecasts

Statistics show that DICE Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. DICE Therapeutics Inc. (DICE) shares have gone down -41.89% during the last six months, with a year-to-date growth rate more than the industry average at 40.76% against -0.10.

Revenue for the current quarter is expected to be $100k as predicted by 2 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $200k by the end of Mar 2022.

While earnings are projected to return -96.20% in 2022.

DICE Dividends

DICE Therapeutics Inc. is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

DICE Therapeutics Inc. (NASDAQ:DICE)’s Major holders

DICE Therapeutics Inc. insiders own 2.32% of total outstanding shares while institutional holders control 73.99%, with the float percentage being 75.75%. RA Capital Management, L.P. is the largest shareholder of the company, while 50 institutions own stock in it. As of Sep 29, 2021, the company held over 5.21 million shares (or 13.62% of all shares), a total value of $170.59 million in shares.

The next largest institutional holding, with 3.15 million shares, is of Sands Capital Ventures, LLC’s that is approximately 8.24% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $103.13 million.

Also, the Mutual Funds coming in first place with the largest holdings of DICE Therapeutics Inc. (DICE) shares are Price (T.Rowe) New Horizons Fund and Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund. Data provided on Sep 29, 2021 indicates that Price (T.Rowe) New Horizons Fund owns about 0.78 million shares. This amounts to just over 2.03 percent of the company’s overall shares, with a $25.43 million market value. The same data shows that the other fund manager holds slightly less at 0.6 million, or about 1.57% of the stock, which is worth about $19.65 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts